{"id":"W4309309141","doi":"10.3390/curroncol29110685","title":"Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Dosing; Pembrolizumab; Medicine; Lung cancer; Pharmacokinetics; Internal medicine; Hazard ratio; Demographics; Cancer; Confidence interval; Demography; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129,0.0001732911,0.0005621995,0.0002317562,0.0001385452,0.0004642321,0.0003501602,0.0003159395,0.001927213],"category_scores_gemma":[0.001489558,0.0001081734,0.0005321778,0.0002265642,0.000181976,0.0004638096,0.0002076238,0.0007428819,0.0002678475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005618297,"about_ca_system_score_gemma":0.000466327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004105217,"about_ca_topic_score_gemma":0.000515389,"domain_scores_codex":[0.999517,0.0001872743,0.00006058156,0.00008276571,0.00009503689,0.00005739605],"domain_scores_gemma":[0.9994166,0.0001715385,0.0002040696,0.00004785887,0.00003589495,0.0001240444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4942015,0.01036857,0.05169808,0.0005012379,0.0006683647,0.000180462,0.0002662029,0.005533742,0.032271,0.0006219176,0.001349462,0.4023395],"study_design_scores_gemma":[0.08766304,0.5680969,0.2850549,0.0001818385,0.001789298,0.001125686,0.0002684779,0.02384816,0.02113255,0.001346268,0.009414342,0.00007847799],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979297,0.0009245681,0.0004296897,0.00005002304,0.00003463406,0.0000876987,0.00005134731,0.00001057782,0.0004816543],"genre_scores_gemma":[0.9989857,0.000236462,0.0004425037,0.00004047745,0.00002176038,0.00007347059,0.00006397642,0.000002943131,0.0001326585],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001927213,"threshold_uncertainty_score":0.006943345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06388930667282215,"score_gpt":0.3812008246949242,"score_spread":0.317311518022102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}